The 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions

Drug Metabolism and Disposition

Volumn 27, Issue 3, 1999, Pages 410-416

  Fischer, Volker ^a   Johanson, Laurie ^a   Heitz, Francis ^a   Tullman, Robert ^a   Graham, Elizabeth ^a   Baldeck, Jean Pierre ^a   Robinson, William T ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYFLUVASTATIN; 6 HYDROXYFLUVASTATIN; CHLORPROPAMIDE; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DRUG METABOLITE; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUINDOSTATIN; GLIBENCLAMIDE; GLIBORNURIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; ITRACONAZOLE; KETOCONAZOLE; MEPHENYTOIN; MIBEFRADIL; N DEISOPROPYLFLUVASTATIN; NIFEDIPINE; PACLITAXEL; PHENACETIN; QUINIDINE; SULFINPYRAZONE; TERBINAFINE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ARTICLE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG INTERACTION; DRUG METABOLISM; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0032937343     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Appel S and Dingemanse J (1996) Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications. Rev Contemp Pharmacother 7:167-182.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
3. Ball SE, Maurer G, Zollinger M, Ladona M and Vickers AEM (1992) Characterization of the cytochrome P-450 gene family responsible for N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metab Dispos 20:56-63.
4. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern Ȧ, Ploschke J and Radtk M (1997) Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25:321-31.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Crespi CL and Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43:171-188.
7. Dain JG, Fu E, Gorski J, Nicoletti J and Scallen TJ (1993) Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 21:567-572.
8. Davidson MH (1994) Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med 96:S41-S44.
9. Dimitroulakos J and Yeger H (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein expressing cells. Nature Med 2:326-33.
10. Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AEM (1998) The multidrug resistance modulator PSC 833 is metabolized by CYP3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26:802-811.
11. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ and Idle JR (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5:389-392.
12. Goldberg R and Roth D (1996) Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation (Baltimore) 62:1559-1564.
13. Ikeda T, Ishigami M, Komai T and Yamazoe Y (1997) Inhibition of hepatic cytochrome P450 isoform, CYP3A, by 3-hydroxy-3-methylglularyl-CoA reductase inhibitors. Atherosclerosis 134:135.
14. Kantola T, Kivistö KT and Neuvonen PJ (1997) Differential effects of itraconazole on fluvastatin and lovastatin pharmacokinetics. Eur J Clin Pharmacol 52:A134.
15. Lees RS and Lees AM (1995) Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 333:664.
16. Levy RI, Troendle AJ and Fattu JM (1993) A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvaslalin. Circulation 87(Suppl 4):III45-III53.
17. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B and Christians U (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311-321.
18. Omura T and Sato R (1964) The carbon-monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
19. Peters TK (1996) Safety profile of fluvastatin. Br J Clin Pract S77a:20-23.
20. Peters TK, Jewitt-Harris J, Mehra M and Muratti EN (1993) Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents: An analysis of a clinical trial database. Am J Hypertens 6:S346-S352.
21. Physicians' Desk Reference (1998) 52nd ed, p 2103. Medical Economics Company, Inc., Montvale, NJ.
22. Plosker GL and Wagstaff AJ (1996) Fluvastatin: A review of its pharmacology and use in the management of hypercholesteraemia. Drugs 51:433-459.
23. Prueksaritanont T, Gorham, LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH and Vyas KP (1997) In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
24. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A and Vigano M (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732-2734.
25. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, pp 161-226. John Wiley & Sons, New York.
26. Tobert JA (1988) Efficacy and long-term adverse effects pattern of lovastatin. Am J Cardiol 62:J28-J34.
27. Transon C, Leemann T and Dayer P (1996) In vitro comparative inhibition of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209-215.
28. Transon C, Leemann T, Vogt N and Dayer P (1995) In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)fluvastatin. Clin Pharmacol Ther 58:412-417.
29. Tse FLS, Jaffe JM and Troendle A (1992) Pbarmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630-638.
30. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP and Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastalin in rat and human liver microsomes. Arch Biochem Biophys 290:355-361.